INOVIO Pharmaceuticals
NEWS ALERT

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Press Releases

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

Posted on December 3, 2024

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Posted on November 14, 2024

Immunology Data Shows INOVIO’s INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

Posted on November 13, 2024

INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024

Posted on November 6, 2024

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

Posted on October 21, 2024

INOVIO to Present at Upcoming Scientific Conferences

Posted on October 1, 2024

INOVIO to Present at Upcoming Scientific Conference

Posted on September 17, 2024

INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Posted on August 8, 2024

Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Posted on July 25, 2024

INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024

Posted on July 25, 2024

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.